Compare Newmont Corporation (NEM) vs 10X Genomics Inc (TXG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Newmont Corporation vs 10X Genomics Inc — how do they compare? Newmont Corporation trades at $93.49 (market cap $95.23B), while 10X Genomics Inc trades at $47.2 (market cap $5.48B). The key difference: Newmont Corporation is far larger — about 17.4× 10X Genomics Inc's market cap, and Newmont Corporation pays a 1.17% dividend while 10X Genomics Inc pays none. Which is the better fit depends on your goals.
| NEM | TXG | |
|---|---|---|
Market Cap | $95.23B | $5.48B |
Sector | Basic Materials | Health |
52-Week High | $131.95 | $45.80 |
52-Week Low | $59.86 | $11.34 |
Enterprise Value | $91.98B | $5.02B |
Dividend Yield | 1.17% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Newmont (NEM) trades at $92.49, up 3.11% today, with a bearish technical signal but strong fundamentals. The stock has beaten earnings estimates for three consecutive quarters, with Q2 2026 results expected soon. Revenue grew to $22.67B in 2025, net income surged to $7.09B, and cash flow from operations hit $10.33B. Analyst consensus is strongly bullish with a $134.63 price target, though technical indicators show selling pressure near resistance at $92.
The outlook is positive given robust profitability, low P/E of 11.57, and gold price tailwinds, but risks include rising unit costs and production volatility. With 76% of analysts rating it Buy and institutional interest steady, NEM offers value if operational execution holds.
TXG trades at $47.20, up 7.91% on the day, with a bullish technical signal from moving averages. The company reported Q1 2026 revenue that beat estimates, and net losses have narrowed significantly from -$255M in 2023 to -$44M in 2025. Operating cash flow turned strongly positive at $136M in 2025. Recent developments include the acquisition of Proteintech Genomics and a collaboration with Cleveland Clinic on bladder cancer diagnostics.
The outlook is mixed; improving fundamentals and strategic expansions support growth, but persistent net losses and a high EV/EBITDA of 133.91 pose valuation risks. Analyst consensus is divided with a $39.14 price target below the current price, indicating caution despite a majority buy/hold ratings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Newmont Corporation
Newmont Corp is primarily a gold producer with operations and/or assets in the United States, Canada, Mexico, Dominican Republic, Peru, Suriname, Argentina, Chile, Australia, and Ghana. It is also engaged in the production of copper, silver, lead and zinc. The company's operations are organized in five geographic regions: North America, South America, Australia, Africa and Nevada.
Read more on NEM →About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →
